| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Research (R.D.D., Z.D., R.C.P., E.C.), Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105-1299; The University of Connecticut School of Medicine (Z.D., E.C.), Farmington, Connecticut 06030; Regeneron Pharmaceuticals, Inc. (A.N.E.), Tarrytown, New York 10591; and Laboratorio de Fisiopatolgia Renal (V.J.), Universidade de São Paulo, São Paulo, Brazil
Address all correspondence and requests for reprints to: Ernesto Canalis, M.D., Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland Street, Hartford, Connecticut 06105-1299. E-mail: ecanalis{at}stfranciscare.org.
Skeletal cells synthesize bone morphogenetic proteins (BMPs) and BMP antagonists. Noggin is a glycoprotein that binds BMPs selectively and antagonizes BMP actions. Noggin expression in osteoblasts is induced by BMPs and noggin opposes the effects of BMPs on osteoblastic differentiation and function in vitro. However, its effects in vivo are not known. We investigated the direct in vivo effects of noggin on bone remodeling in transgenic mice overexpressing noggin under the control of the osteocalcin promoter. Noggin transgenics suffered long bone fractures in the first month of life. Total, vertebral, and femoral bone mineral densities were reduced by 23–29%. Static and dynamic histomorphometry of the femur revealed that noggin transgenic mice had decreased trabecular bone volume, number of trabeculae, and bone formation rate. Osteoblast surface and number of osteoblasts/trabecular area were not significantly decreased, indicating impaired osteoblastic function. Osteoclast surface and number were normal/decreased, there was no increase in bone resorption, and the tissue had the appearance of woven bone. Vertebral microcomputed tomography scanning confirmed decreased trabecular bone volume and trabecular number. In conclusion, transgenic mice overexpressing noggin in the bone microenvironment have decreased trabecular bone volume and impaired osteoblastic function, leading to osteopenia and fractures.
This article has been cited by other articles:
 |
|
 |
|
  A. E. Merrill, B. F. Eames, S. J. Weston, T. Heath, and R. A. Schneider Mesenchyme-dependent BMP signaling directs the timing of mandibular osteogenesis Development, April 1, 2008; 135(7): 1223 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gazzerro, A. Smerdel-Ramoya, S. Zanotti, L. Stadmeyer, D. Durant, A. N. Economides, and E. Canalis Conditional Deletion of Gremlin Causes a Transient Increase in Bone Formation and Bone Mass J. Biol. Chem., October 26, 2007; 282(43): 31549 - 31557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Wan, J. H. Pomerantz, L. J. Brunet, J.-B. Kim, Y.-F. Chou, B. M. Wu, R. Harland, H. M. Blau, and M. T. Longaker Noggin Suppression Enhances in Vitro Osteogenesis and Accelerates in Vivo Bone Formation J. Biol. Chem., September 7, 2007; 282(36): 26450 - 26459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schwaninger, C. A. Rentsch, A. Wetterwald, G. van der Horst, R. L. van Bezooijen, G. van der Pluijm, C. W.G.M. Lowik, K. Ackermann, W. Pyerin, F. C. Hamdy, et al. Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases Am. J. Pathol., January 1, 2007; 170(1): 160 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Fritz, S. Jiang, J. Xu, and M. B. Rogers A Polymorphism in a Conserved Posttranscriptional Regulatory Motif Alters Bone Morphogenetic Protein 2 (BMP2) RNA:Protein Interactions Mol. Endocrinol., July 1, 2006; 20(7): 1574 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noda BMP and Its Antagonists IBMS BoneKEy, April 1, 2006; 3(4): 5 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Loots, M. Kneissel, H. Keller, M. Baptist, J. Chang, N. M. Collette, D. Ovcharenko, I. Plajzer-Frick, and E. M. Rubin Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease Genome Res., July 1, 2005; 15(7): 928 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gazzerro, R. C. Pereira, V. Jorgetti, S. Olson, A. N. Economides, and E. Canalis Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia Endocrinology, February 1, 2005; 146(2): 655 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Winkler, C. Yu, J. C. Geoghegan, E. W. Ojala, J. E. Skonier, D. Shpektor, M. K. Sutherland, and J. A. Latham Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex J. Biol. Chem., August 27, 2004; 279(35): 36293 - 36298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mishina, M. W. Starbuck, M. A. Gentile, T. Fukuda, V. Kasparcova, J. G. Seedor, M. C. Hanks, M. Amling, G. J. Pinero, S.-i. Harada, et al. Bone Morphogenetic Protein Type IA Receptor Signaling Regulates Postnatal Osteoblast Function and Bone Remodeling J. Biol. Chem., June 25, 2004; 279(26): 27560 - 27566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhao, M. Qiao, S. E. Harris, B. O. Oyajobi, G. R. Mundy, and D. Chen Smurf1 Inhibits Osteoblast Differentiation and Bone Formation in Vitro and in Vivo J. Biol. Chem., March 26, 2004; 279(13): 12854 - 12859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zakin and E. M. De Robertis Inactivation of mouse Twisted gastrulation reveals its role in promoting Bmp4 activity during forebrain development Development, January 15, 2004; 131(2): 413 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Glaser, A. N. Economides, L. Wang, X. Liu, R. D. Kimble, J. P. Fandl, J. M. Wilson, N. Stahl, F. S. Kaplan, and E. M. Shore In Vivo Somatic Cell Gene Transfer of an Engineered Noggin Mutein Prevents BMP4-Induced Heterotopic Ossification J. Bone Joint Surg. Am., December 1, 2003; 85(12): 2332 - 2342. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
